<DOC>
	<DOCNO>NCT00631189</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Rosuvastatin 5 mg hypercholesterolemia treatment comparatively 2 statin : Pravastatin 40 mg Atorvastatin 10 mg . Treatment efficacy evaluate percentage LDL-C variation 8 week treatment .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Rosuvastatin 5 mg Versus Pravastatin 40 mg Atorvastatin 10 mg Type IIa IIb Hypercholesterolaemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>subject present type IIa IIb primary hypercholesterolaemia diagnose least 3 month , context primary prevention least two associated cardiovascular risk factor : ( ) either `` naive '' lipidlowering therapy , ( ii ) treat statin ( treatment ongoing stop previous 8 week ) homozygous heterozygous familial hypercholesterolaemia hypertriglyceridaemia ( TG â‰¥ 4 g/l ) subject high cardiovascular risk accord AFSSAPS 2005 definition ( coronary artery disease history document vascular disease , high cardiovascular risk type 2 diabetes , subject primary prevention 10year CHD risk &gt; 20 % ) history adverse event hypersensitivity HMG CoA reductase inhibitor ( particularly history myopathy ) concomitant use drug authorize study active liver disease elevation serum transaminase ( ASAT , ALAT ) twice upper limit normal CPK 3 time upper limit normal moderate severe renal failure ( creatinine clearance &lt; 6 ml/min ) poorly control hypothyroidism ; poorly control hypertension ( DBP &gt; 95 mm Hg and/or SBP &gt; 180 mm Hg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>dyslipidemia</keyword>
</DOC>